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E-mail address: ozturkm@ujf-grenoble.fr (M. OztCellular senescence is a process leading to terminal growth arrest with characteristic mor-
phological features. This process is mediated by telomere-dependent, oncogene-induced
and ROS-induced pathways, but persistent DNA damage is the most common cause. Senes-
cence arrest is mediated by p16INK4a- and p21Cip1-dependent pathways both leading to ret-
inoblastoma protein (pRb) activation. p53 plays a relay role between DNA damage sensing
and p21Cip1 activation. pRb arrests the cell cycle by recruiting proliferation genes to facul-
tative heterochromatin for permanent silencing. Replicative senescence that occurs in
hepatocytes in culture and in liver cirrhosis is associated with lack of telomerase activity
and results in telomere shortening. Hepatocellular carcinoma (HCC) cells display inactivat-
ing mutations of p53 and epigenetic silencing of p16INK4a. Moreover, they re-express telo-
merase reverse transcriptase required for telomere maintenance. Thus, senescence bypass
and cellular immortality is likely to contribute signiﬁcantly to HCC development. Onco-
gene-induced senescence in premalignant lesions and reversible immortality of cancer
cells including HCC offer new potentials for tumor prevention and treatment.
 2008 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Senescence is an evolutionary term meaning ‘‘the pro-
cess of becoming old”; the phase from full maturity to
death characterized by accumulation of metabolic prod-
ucts and decreased probability of reproduction or survival
[1]. The term ‘‘cellular senescence” was initially used by
Hayﬂick and colleagues to deﬁne cells that ceased to divide
in culture [2]. Today, cellular senescence is recognized as a
response of proliferating somatic cells to stress and dam-
age from exogenous and endogenous sources. It is charac-
terized by permanent cell cycle arrest. Senescent cells also
display altered morphology and an altered pattern of gene
expression, and can be recognized by the presence ofand Ltd. All rights reserved.
herche INSERM-Uni-
iot, Grenoble 38000,
6 54 94 54.
urk).senescence markers such as senescence-associated
b-galactosidase (SABG), p16INK4A, senescence-associated
DNA-damage foci and senescence-associated heterochro-
matin foci (for a review see Ref. [3]). This cellular response
has both beneﬁcial (anti-cancer) and probably deleterious
(such as tissue aging) effects on the organism. Most of
our knowledge of cellular senescence is derived from
in vitro studies performed with ﬁbroblasts, and some epi-
thelial cells such as mammary epithelial cells. Animal
models are increasingly being used to study cellular senes-
cence in vivo. Telomerase-deﬁcient mouse models lacking
RNA subunit (TERC/) have been very useful in demon-
strating the critical role of telomeres in organ aging and tu-
mor susceptibility [4]. Other mouse models including
tumor suppressor gene-deﬁcient and oncogene-expressing
mice were also used extensively.
Compared to other tissues and cancer models, the role
of senescence in liver cells and its implications in hepato-
cellular carcinogenesis have been less explored. One of
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As hepatocytes can not divide in cell culture, the study of
their replicative senescence mechanisms is not easy. Nev-
ertheless, these cells are able to quit their quiescent state
in vivo and proliferate massively in response to partial
hepatectomy or liver injury [5]. This capacity can be ex-
plored to study in vivo senescence of hepatocytes using ro-
dent models. Studies with clinical samples indicate that
hepatocyte senescence occurs in vivo in patients with
chronic hepatitis, cirrhosis and HCC [6–8]. In contrast to
the paucity of studies directly addressing cellular senes-
cence, the critical role of telomere shortening (as a feature
associated with replicative senescence) in cirrhosis and
HCC development is well established [9]. Telomeres in nor-
mal liver show a consistent but slow shortening during
aging. In contrast, hepatocyte DNA telomere shortening is
accelerated in patients with chronic liver disease with
shortest telomeres described in cirrhotic liver and HCC.
Telomerase-deﬁcient mice have also been used elegantly
to demonstrate the critical roles of telomerase and telo-
meres in liver regeneration and experimentally induced
cirrhosis [10,11]. A major accomplishment in recent years
was the demonstration of critical role played by senes-
cence for the clearance of ras-induced murine liver carci-
nomas following p53 restoration [12].
Despite a relatively important progress, the mecha-
nisms of hepatocellular senescence and the role of cellular
immortality in HCC remain ill-known issues. As one of the
rare tissues with ample clinical data on senescence-related
aberrations, liver may serve as an excellent model to fur-
ther explore the relevance of cellular senescence in human
biology. Moreover, a better understanding of senescence
and immortality in hepatic tissues may help to develop
new preventive and therapeutic approaches for severe li-
ver diseases such as cirrhosis and HCC. Here we will review
recent progress on senescence and immortality mecha-
nisms with a speciﬁc emphasis on hepatocellular
carcinogenesis.2. Senescence pathways
Cellular senescence has long been considered as a
mechanism that limits the number of cell divisions (or
population doublings) in response to progressive telomere
shortening. Most human somatic cells are telomerase-deﬁ-
cient because of the repression of telomerase reverse
transcriptase (TERT) expression. Therefore, proliferating
somatic cells undergo progressive telomere DNA erosion
as a function of their number of cell divisions. This form
of senescence is now called as replicative or telomere-
dependent senescence (Fig. 1).
Human chromosome telomere ends are composed of
TTAGGG repeats (5–20 kb) in a DNA-protein complex
formed by six telomere-speciﬁc proteins, called ‘‘shelterin”
[13]. Telomeric DNA has a structure called ‘‘t-loop” which
is formed as a result of invasion of the single stranded G-
rich sequence into the double-stranded telomeric tract.
Since the 1930s, it has been known that telomeres, with
telomere-binding proteins, prevent genomic instability
and the loss of essential genetic information by ‘‘capping”chromosome ends. They are also indispensable for proper
recombination and chromosomal segregation during cell
division. Telomeres become shorter with every cell divi-
sion in somatic cells, because of replication complex’s
inability to copy the ends of linear DNA, which also makes
them a ‘‘cell cycle counter” for the cell [14]. Telomeres are
added to the end of chromosomes with a complex contain-
ing the RNA template TERC and the reverse transcriptase
TERT [15]. Most somatic cells lack telomerase activity be-
cause the expression of TERT is repressed, in contrast to
TERC expression. The lack of sufﬁcient TERT expression in
somatic cells is the main cause of telomere shortening dur-
ing cell replication. This telomerase activity also helps to
maintain telomere integrity by telomere capping [15].
The loss of telomeres has long been considered to be the
critical signal for senescence induction. It is now well
known that telomere-dependent senescence is induced
by a change in the protected status of shortened telomeres,
whereby the loss of telomere DNA contributes to this
change [16]. The loss of telomere protection or any other
cause of telomere dysfunction results in inappropriate
chromosomal end-to-end fusions through non-homolo-
gous end joining or homologous recombination DNA repair
pathways [17]. These DNA repair pathways are used prin-
cipally to repair double-strand DNA breaks (DSBs). Thus, it
is highly likely that the open-ended telomere DNA is
sensed as a DSB by the cell machinery when telomere
structure becomes dysfunctional. Accordingly, dysfunc-
tional telomeres elicit a potent DSB type DNA damage re-
sponse by recruiting phosphorylated H2AX, 53BP1, NBS1
and MDC1 [18].
Telomere-dependent senescence is not the only form of
senescence. At least two other forms of telomere-indepen-
dent senescence are presently known: (1) oncogene-in-
duced senescence; and (2) reactive oxygen species (ROS)-
induced senescence (Fig. 1).
Oncogene-induced senescence had initially been identi-
ﬁed as a response to expression of Ras oncogene in normal
cells ([19], for a recent review see [20]). The expression of
oncogenic Ras in primary human or rodent cells results in
permanent G1 arrest. The arrest was accompanied by accu-
mulation of p53 and p16INK4a, and was phenotypically
indistinguishable from cellular senescence. This landmark
observation suggested that the onset of cellular senescence
does not simply reﬂect the accumulation of cell divisions,
but can be prematurely activated in response to an onco-
genic stimulus [19]. In 10 years following this important
discovery, telomere-independent forms of senescence have
become a new focus of extensive research leading to the
recognition of senescence as a common form of stress re-
sponse. Moreover, oncogene-induced senescence is now
recognized as a novel mechanism contributing to the ces-
sation of growth of premalignant or benign neoplasms to
prevent malignant cancer development [21]. In addition
to Ras, other oncogenes including Raf, Mos, Mek, Myc
and Cyclin E also induce senescence [20]. Conversely, the
loss of PTEN tumor suppressor gene also leads to senes-
cence [22]. Similar to telomere-dependent senescence,
oncogene-induced senescence is also primarily a DNA
damage response (Fig. 1). Experimental inactivation of
DNA damage response abrogates Ras-induced senescence
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Fig. 1. DNA damage and p53 activation play a central role in different senescence pathways. DNA damage (often in the form of double-strand breaks)
activate upstream kinases (ATM and ATR) leading to p53 phosphorylation by CHK1 and CHK2 kinases. Phosphoryated p53 is released from MDM, and
stabilized in order to induce senescence arrest or apoptosis (not shown here).
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and oncogene-induced senescence are established follow-
ing DNA hyper-replication immediately after oncogene
expression. Senescent cells arrest with partly replicated
DNA, where DNA replication origins have ﬁred multiple
times, prematurely terminated DNA replication forks and
DNA double-strand breaks are present [23,24].
ROS-induced senescence, the other telomere-indepen-
dent senescence pathway is gaining importance (for a re-
cent review see Ref. [25]). Mitochondria are the major
intracellular sources of ROS which are mainly generated
at the respiratory chain. Therefore, ROS have been sus-
pected for many years as cellular metabolites involved in
organismal aging [26]. ROS are also generated in the cyto-
plasm by the NOX family of enzymes [27]. Experimental
induction of ROS accumulation in cells (for example by
mild H2O2 treatment or glutathione depletion) induces
senescence-like growth arrest in different cell types,
whereas anti-oxidant treatment can inhibit senescence
[25]. More importantly, ROS have been identiﬁed as critical
mediators of both telomere-dependent and oncogene-in-
duced senescence. Telomere-dependent senescence arrestis accelerated in cells grown under high O2 conditions. In-
versely, cells grown under low O2 conditions display in-
creased lifespan ([28], see Ref. [25]). ROS also play a
critical role in Ras-induced senescence [29,30].
Currently, mechanisms of ROS-induced senescence are
not fully understood. It is generally accepted that oxidative
stress and ROS eventually cause DNA damage, whereby
DNA damage response may contribute to senescence
induction. The relationship between mitochondrial dys-
function, ROS, DNA damage and telomere-dependent
senescence has recently been demonstrated [31]. However,
ROS may also induce modiﬁcations in the cellular signaling
pathways resulting in senescence arrest. For example, ROS
induce senescence in hematopoietic stem cells by activat-
ing p38 MAPK [32].
Whether induced by telomere dysfunction, DNA repli-
cation stress following oncogene activation, or ROS accu-
mulation, DNA damage is one of the common steps in
the generation of senescence arrest via p53 activation
(Fig. 1). Upstream checkpoint kinases, such as ATM or
ATR are activated in response to DNA damage in the form
of double-stand breaks. These kinases phosphorylate
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phosphorylate p53. Phosphorylation of p53 results in its
activation by the displacement of the MDM2 protein. Crit-
ical involvement of this p53 activating pathway has been
reported for both telomere-dependent [33], and onco-
gene-induced senescence [34].
Other mechanisms of senescence that are apparently
not driven by DNA damage should also be discussed here.
Of particular interest is the INK4 locus encoding two inhib-
itors of cyclin-dependent kinases (p16INK4a, p15INK4b), and
ARF, a p53 regulatory protein (for a review see Ref. [35]).
p16INK4a and p15INK4b connect some senescent initiating
signals to the retinoblastoma (Rb) pathway, independent
of p53 activation. These proteins are easily activated in cell
culture and induce senescence arrest. Cells that escape
senescence often display inactivation of p16INK4a, and
sometimes p15INKb and ARF either by homozygous deletion
or by shutting-down gene expression. A prominent role for
p16INK4a in senescence and tumor suppression in humans
has emerged, despite some confusion due to the fact that
a relatively small DNA segment encodes the 3 proteins of
the INK4 locus. p16INK4a is activated during telomere-
dependent and oncogene-induced senescence [19,36].
Moreover, its expression is induced in aging tissues [37].
The mechanisms of regulation of p16INK4a expression are
not well known. Although individual components of INK4
locus can respond independently to positively – (for exam-
ple to Ras) or negatively – (for example c-Myc) acting sig-
nals, the entire INK4 locus might be coordinately regulated
by epigenetic mechanisms (reviewed in Ref. [35]).
A very recent addition to the list of senescence mecha-
nisms is to be qualiﬁed as ‘‘senescence induced by secreted
proteins”. It was reported many years ago that TGF-b is a
mediator of oncogene-induced senescence [38]. This
mechanism of induction is of particular interest, because
it suggests that not only intrinsic cellular factors, but also
extracellular or secreted proteins can induce senescence.
Recent discovery of several other secreted proteins, includ-
ing IGFBP7 and IL6 as autocrine/paracrine mediators of
oncogene-induced senescence arrest, provide strong sup-
port for an extracellularly induced form of senescence
[39–41]. This new form of senescence regulation is remi-
niscent of the so called active apoptosis induction by death
ligands. Thus, an active form of cellular senescence in-
duced by ‘‘aging ligands” could be a major physiological
regulator of tissue/organism aging.
3. Cyclin-dependent inhibitors as commonmediators of
senescence arrest
We have already stated that senescence and apoptosis
share interesting similarities. Another similarity between
these cellular processes is the convergence of different
pathways in a common place to induce the same cell fate,
independent of the initial signal. Similarly to caspase acti-
vation, prior to apoptosis induction by different stimuli,
most if not all senescence pathways result in the activation
of cyclin-dependent kinase inhibitors (CDKIs) in order to
induce permanent cell cycle arrest. Senescent cells accu-
mulate at G1 phase of the cell cycle due to an inability toenter into S phase in order to initiate DNA synthesis. The
transition of proliferating cells from G1 to S phase requires
the release of E2F factors from their inhibitory partner ret-
inoblastoma protein (pRb) following phosphorylation by
cyclin-dependent kinases (CDKs), in particular by CDK4/
CDK6 and CDK2 at this stage of the cycle [35]. The senes-
cence arrest is mediated by inhibition of pRb phosphoryla-
tion by CDK4 and CDK2. The activities of these enzymes are
controlled by different mechanisms, but the major proteins
involved in the control of senescence arrest are CDKIs. Al-
most all known CDKIs have been reported to be implicated
in senescence arrest, but three of them are best character-
ized: p16INK4a and p15INK4b which inhibit CDK4/CDK6, and
p21Cip1 which inhibits CDK2 (Fig. 2).
p21Cip1 is one of the main targets of p53 for the induc-
tion of cell cycle arrest following DNA damage [42]. Path-
ways that generate DNA damage response and p53
activation use p21Cip1 as a major mediator of cellular
senescence to control pRb protein [43]. Exceptionally,
p21Cip1 can be activated by p53-independent pathways to
induce senescence [44].
The Rb protein plays two important and complemen-
tary roles that are necessary to initiate and to permanently
maintain the cell cycle arrest in senescent cells. pRb pro-
teins ﬁrstly contribute to the exit from the cell cycle by
arresting cells at G1 phase, as expected [45]. In senescent
cells, this exit is complemented with a dramatic remodel-
ing of chromatin through the formation of domains of fac-
ultative heterochromatin called SAHF [46–48]. SAHF
contain modiﬁcations and associated proteins characteris-
tic of transcriptionally silent heterochromatin. Prolifera-
tion-promoting genes, such as E2F target genes are
recruited into SAHF in a pRb protein-dependent manner.
This recruitment is believed to contribute to irreversible
silencing of these proliferation-promoting genes [49].
4. Senescence of hepatocytes and chronic liver disease
Hepatocytes in the adult liver are quiescent cells, they
are renewed slowly, approximately once a year, as esti-
mated by telomere loss which is 50–120 bp per year in
healthy individuals [50,51]. However, the liver has an ex-
tremely powerful regenerative capacity, as demonstrated
experimentally in rodents, and as observed in patients
with chronic liver diseases [5]. This regenerative capacity
is due mostly to the ability of mature hepatocytes to prolif-
erate in response to a diminution of total liver mass either
experimentally, or following exposure to viral and non vir-
al hepatotoxic agents. In addition, the adult liver seems to
harbor hepatocyte-progenitor cells (<0.10% of total hepato-
cyte mass) that are able to restore liver hepatocyte popula-
tions [52]. However, hepatocytes, like any other somatic
cells, do not have unlimited replicative capacity, due to
the lack of telomerase activity that is needed to avoid telo-
mere shortening during successive cell divisions. This is
best exempliﬁed by decreased hepatocyte proliferation in
liver cirrhosis stage of chronic liver diseases [53], providing
in vivo evidence for the exhaustion of hepatocyte prolifer-
ation capacity. Senescence mechanisms in hepatocytes and
in liver tissue are not well known. However, a limited
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numerous descriptive in vivo studies in liver tissue provide
sufﬁcient evidence that hepatocytes can undergo senes-
cence type changes.
In vitro senescence in hepatocytes: as stated earlier,
limited proliferative capacity of somatic cells is controlled
by replicative senescence. The experimental study of repli-
cative senescence is done traditionally by serial culture of
primary cells. Initially observed in ﬁbroblasts, this phe-
nomenon has also been well understood in some epithelial
cells, mammary epithelial cells in particular [54]. On the
other hand, our knowledge of hepatocyte replicative senes-
cence is highly limited. In contrast to in vivo conditions,
mature hepatocytes are extremely resistant to cell prolifer-
ation in cell culture. Usually, more than 99.9% of adult liver
hepatocytes do not divide and can only be maintained in
culture for a few weeks at most. A small progenitor-type
cell population (so called small hepatocytes) has been
shown to proliferate in vitro, but they usually stop growing
at passages 5–7, with an ill-deﬁned senescence-like pheno-
type [55].
Fetal hepatocytes display better proliferation capacity
in culture. A few studies have shown that these fetal cells
enter replicative senescence, as shown by senescence-
associated b-galactosidase assay (SABG) at population dou-
bling (PD) 30–35 [55]. This is accompanied by progressive
shortening of telomeres down to 6 kbp, as these cells like
adult hepatocytes lack telomerase activity. However, it was
possible to immortalize these fetal hepatocytes by stableexpression of TERT [55]. Such immortalized cells have been
expanded beyond known senescence barriers (>300 PD).
In vivo senescence in liver tissue: in contrast to in vitro
studies, in vivo senescence of human hepatocytes is better
known. Indeed, the liver is one of the rare tissues where
in vivo evidence for senescence has been convincingly
and independently demonstrated by different investigators
[6–9]. Replicative senescence (as tested by SABG assay)
displayed a gradual increase from 10% in normal liver, to
84% in cirrhosis ([6,7]. It was also detected in 60% HCCs
[6]. It has also been demonstrated that telomere shorten-
ing in cirrhosis is restricted to hepatocytes and this hepa-
tocyte-speciﬁc shortening was correlated with SABG
staining [7].
Potential mechanisms of senescence in hepatocytes and
the liver: as presented in detail in the previous section,
multiple pathways of senescence have been described in
different experimental systems. Key molecules that are al-
ready involved in senescence arrest have also been sum-
marized. The published data on different senescence
pathways in the liver is fragmented and control mecha-
nisms involved in hepatocyte senescence are not com-
pletely understood. Therefore, existing data on
hepatocellular senescence together with potential mecha-
nisms that may be involved in this process will be
presented.
For reasons previously described, almost nothing is
known about molecular mechanisms involved in replica-
tive senescence and immortalization of hepatocytes in cul-
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immortalization in vitro. Thus, ectopically expressed TERT
may induce hepatocyte immortalization. However, as the
published data using TERT immortalization is scarce, it is
highly likely that the immortalization of hepatocytes is
not an easy task even with a well-established protocol that
works with other epithelial cell types such as mammary
epithelial cells. The mechanisms of in vitro senescence
induction in hepatocytes are also mostly unknown. Rapid
induction of a senescence arrest in cultured hepatocytes
suggests that these cells display robust telomere-indepen-
dent senescence-inducing systems that are functional
in vitro. However, they remain to be discovered. It is highly
likely that, similar to other somatic cells, p53 and RB path-
ways in general, and some CDKIs in particular are also in-
volved in hepatocyte senescence, but the evidence is
lacking for the time being.
Telomere shortening during aging is slow (55–120 base
pairs per year) and stabilizes at mid age in healthy liver, so
that the loss of telomeric DNA does not reach a level to in-
duce telomere dysfunction and DNA damage response
[50,51]. Other forms of telomere-independent senescence
such as ROS-induced senescence may also be rare under
normal physiological conditions. On the other hand, telo-
mere loss is accelerated in chronic liver disease to reach
lowest levels in the cirrhotic liver [7,51]. Therefore, one
plausible mechanism involved in cirrhosis is probably telo-
mere-dependent senescence, or replicative senescence.
The relevance of replicative senescence to liver tissue aging
has been demonstrated experimentally using telomerase-
deﬁcient mice. Late generation telomerase-deﬁcient mice
display critically shortened telomeres and an impaired li-
ver growth response to partial hepatectomy. A subpopula-
tion of telomere-shortened hepatic cells displayed
impaired proliferative capacity that is associated with
SABG activity [11,56]. On the other hand, it has been re-
ported that mouse liver cells are highly resistant to exten-
sive telomere dysfunction. Conditional deletion of the
telomeric protein TRF2 in hepatocytes resulted in telomer-
ic accumulation of phospho-H2AX and frequent telomere
fusions, indicating loss of telomere protection. However,
there was no induction of p53 and liver function appeared
unaffected. The loss of TRF2 did not compromise liver
regeneration after partial hepatectomy. Liver regeneration
occurred without cell division involving endoreduplication
and cell growth, thereby circumventing the chromosome
segregation problems associated with telomere fusions.
Thus, it appears that hepatocytes display intrinsic resis-
tance to telomere dysfunction, although they are appar-
ently vulnerable to severe telomere loss [57].
Hepatocyte senescence that is observed in severe
chronic liver diseases such as cirrhosis may also be induced
by telomere-independent pathways. Chronic liver injury
observed under such conditions is accompanied with
inﬂammation, cell death, and oxidative stress [58–60].
Some of the etiological factors such as HCV and alcohol in-
duce mitochondrial dysfunction may result in ROS accu-
mulation [61,62]. Thus, ROS-induced senescence may also
occur during cirrhosis, although this has not yet been re-
ported. The status of DNA damage in chronic liver disease
is less well-known. 8-Hydroxydeoxyguanosine, an indica-tor of DNA lesions produced by ROS, was reported to be in-
creased in chronic liver disease [63]. On the other hand, the
upregulation of DNA repair enzymes in cirrhosis has also
been reported [64]. Increased DNA repair activity in cirrho-
sis which may reﬂect increased DNA damages as a conse-
quence of chronic liver injury, but also inhibition of DNA
damage responses such as senescence were observed. Ta-
ken together, these observations suggest that the primary
cause of senescence in cirrhotic patients is telomere dys-
function and that ROS may also play additional roles.
Among senescence-related proteins, p16INK4a and
p21Cip1 expression was found to be high in cirrhosis, as
compared to normal liver and tumor tissues [65], suggest-
ing that these major senescence-inducing proteins accu-
mulate in the cirrhotic liver. Promoter methylation of
these CDKIs was also studied. Chronic liver disease sam-
ples displayed lower levels of methylation as compared
to HCCs [66]. Thus, the progression of chronic liver disease
towards cirrhosis is accompanied with a progressive acti-
vation of different CDKIs, as expected.5. Senescence pathway aberrations and telomerase
reactivation in hepatocellular carcinoma
As stated earlier, p53 and retinoblastoma (Rb) pathways
play a critical role in senescence arrest as observed in dif-
ferent in vitro and in vivo models. Indirect evidence sug-
gests that these pathways may also be important in
hepatocellular senescence. The accumulation of p21 and
p16 in cirrhotic liver tissues has been reported indepen-
dently by different reports. On the other hand, HCC rarely
develops in liver tissues absent of chronic liver disease.
More than 80% of these cancers are observed in patients
with cirrhosis [9]. As the appearance of proliferating malig-
nant cells from this senescence stage requires the bypass of
senescence, the status of both p53 and RB pathways in HCC
is of great importance in terms of molecular aspects of
hepatocellular carcinogenesis.
HCC is one of the major tumors displaying frequent p53
mutations [67,68]. The overall p53 mutation frequency in
HCC is around 30%. Both the frequency and the spectrum
of p53 mutations show great variations between tumors
from different geographical areas of the World. A hotspot
mutation (codon 249 AGG? AGT) has been linked to
exposure to aﬂatoxins which are known to be potent
DNA damaging agents (for a review see Ref. [67]).
Although, it is unknown whether aﬂatoxins are able to
generate a DNA damage-dependent senescence response
in hepatocytes, their association with DNA damage and
p53 mutation provides indirect evidence for such an abil-
ity. Other p53 mutations described in HCCs from low aﬂa-
toxin areas may similarly be correlated with other DNA
damaging agents, such as ROS which are known to accu-
mulate in the livers of patients with chronic liver diseases,
including cirrhosis.
Another player of senescence arrest, the p16 gene is
rarely mutated in HCC, but its epigenetic silencing by pro-
moter methylation is highly frequent in this cancer. More
than 50% of HCCs display de novo methylation of the pro-
moter of CDKN2A gene, encoding p16 protein, resulting in
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Rb pathways in the same set of HCCs with different etiolo-
gies have been analyzed [69]. Retinoblastoma pathway
alterations (p16 INK4a, p15INK4b or RB1 genes) were present
in 83% of HCCs, whereas p53 pathway alterations (p53 or
ARF genes) were detected in only 31% of tumors. Altera-
tions in both Rb and p53 pathways were present in 30%
of HCCs. Thus, it appears that either the Rb and/or the
p53 pathway are affected in the great majority of HCCs,
and that both pathways are affected in at least one third
of these tumors. Unfortunately, p53 and p16INK4a aberra-
tions observed in HCC have not yet been studied in relation
to senescence aberrations. However, these observations
provide supporting evidence on the critical role of senes-
cence-controlling pathways in the development of HCC.
The lack of telomerase activity in normal and cirrhotic
liver correlates with progressive loss of telomere
sequences ending up with a senescence arrest. The
emergence of malignant hepatocytes from this senes-
cence-dominated cirrhotic milieu would require not only
the bypass of senescence, but also a way of survival despite
critically shortened telomeres. Additionally, the prolifera-
tive expansion of neoplastic cells in order to form
sustained tumor masses would require telomeres at a min-
imal length required to maintain intact chromosomal
structures.
Many studies showed that telomerase activity is a hall-
mark of all human cancers, including 80–90% of HCCs
[70–72]. It is currently unclear how the TERT expression
is repressed and released in normal hepatocytes and HCC
cells, respectively. The integration of HBV DNA sequences
into TERT gene provides evidence for a virus-induced
deregulation of TERT expression, but this appears to rarely
occur, as only four cases have been reported thus far [73–
75]. Hbx and PreS2 proteins may upregulate TERT expres-
sion [76,77]. The molecular mechanisms involved in TERT
suppression in somatic cells and its reactivation in cancer
cells are ill-known. The TERT promoter displays binding
sites for a dozen of transcriptional regulators: estrogen
receptor, Sp1, Myc and ER81 acting positively, and vitamin
D receptor, MZF-2, WT1, Mad, E2F1 and SMAD interacting
protein-1 (SIP1, also called ZEB-2 or ZFHX1B) acting nega-
tively [78]. Despite high telomerase activity, telomeres in
HCC were repeatedly found to be highly shortened
[65,79,80]. However, 30 telomere overhangs were found
to be increased in nearly 40% HCCs [80]. Moreover, the
expression of several telomeric proteins is increased in
HCC [80,81].
Another ill-known aspect of TERT activity in HCC cells is
the cellular origin of these malignant cells. It is presently
unclear whether HCC arises from mature hepatocytes
which lack telomerase activity, or stem/progenitor cell-like
cells that may already express TERT at sufﬁcient levels to
maintain telomere integrity. In the non-tumor area sur-
rounding the cancer tissue, telomerase activity could not
be detected, or was detected at very low levels.
The importance of telomerase activity in HCC
development has been studied experimentally using telo-
merase-deﬁcient mouse model. These mice show in-
creased susceptibility to adenoma development (tumor
initiation), but they are quite resistant to fully malignanttumor development [82]. Likewise, telomerase deletion
limits the progression of p53-mutant HCCs with short telo-
meres [83]. These observations suggest that the aberra-
tions affecting telomerase activity and senescence
controlling genes such as p53 may cooperate during hepa-
tocellular carcinogenesis.
In summary, HCC is characterized by mutational inacti-
vation of p53, a major player in DNA damage-induced
senescence. In addition, p15INK4b, p16INK4a, p21Cip1 CDKIs
are often inactivated in this cancer mostly by epigenetic
mechanisms involving promoter methylation. These
changes may play a critical role in the bypass of senescence
that is observed in most cirrhosis cases, allowing some ini-
tiated cells to escape senescence control and proliferate. In
the absence of telomerase activity such cells would proba-
bly not survive due to telomere loss. However, since more
than 80% of HCCs display telomerase activity, it is highly
likely that the telomerase reactivation, together with the
inactivation of major CDKIs, plays a critical role in HCC
development by conferring premalignant or malignant
cells the ability to proliferate indeﬁnitely (Fig. 3). However,
cellular immortality is not sufﬁcient for full malignancy
[84]. Thus, senescence-related aberrations that are ob-
served in HCC cells, may confer a partial survival advan-
tage that would need to be complemented by other
genetic or epigenetic alterations.6. Senescence as an anti-tumor mechanism in
hepatocellular carcinoma
Senescence in normal somatic cells and tissues is ex-
pected. How about cancer cells and tumors? Initial studies
using different cancer cell lines provided ample evidence
for the induction of senescence by different genetic as well
as chemical or biological treatments [85]. Thus, it appeared
that cancer cells, immortalized by deﬁnition, do have a
hidden senescence program that can be revealed by differ-
ent senescence-inducing stimuli. These studies provided
preliminary evidence for considering senescence induction
as an anti-cancer therapy. The in vivo relevance of these
observations and expectations became evident only very
recently. Senescence was observed in tumors or pre-neo-
plastic lesions. SABG activity as well as several other senes-
cence markers were detected in lung adenomas, but not in
adenocarcinomas observed in oncogenic Ras ‘‘knock-in”
mice [86]. Ras-driven mouse T-cell lymphomas entered
senescence after drug therapy, when apoptosis was
blocked [87]. The ﬁrst direct evidence of cellular senes-
cence in humans was reported for the melanocytic nevus
[88].
Senescence response of HCC cells was not the subject of
intensive study until very recently. Therefore the potential
role of senescence in these tumors is less well understood.
Treatment of HCC cell lines with 5-aza-2-deoxycytidine in-
duced the expression of p16INK4a, hypophosphorylation of
pRb and G1 arrest associated with positive SABG staining
[89]. Recent ﬁndings indicate that senescence induction
is a powerful mechanism of HCC regression. Xue et al. ex-
pressed H-ras oncogene and suppressed endogenous p53
expression in mouse hepatoblasts which produced massive
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Fig. 3. Role of cellular senescence and immortalization in hepatocellular carcinogenesis. Chronic liver injury (triggered by major etiological factors HBV,
HCV and alcohol) leading to cirrhosis is a common cause of HCC. Hepatocytes having no telomerase activity undergo progressive telomere shortening and
DNA damage during this process. Consequently, CDKIs (primarily p16INK4a and p21Cip1) are activated gradually to induce senescence in the preneoplastic
cirrhosis stage. Mutation and expression analyses in HCC strongly suggest that neoplastic cells bypass the senescence barrier by inactivating major
senescence-inducing genes (p53, p16INK4a and p15INK4b). Moreover, they acquire the ability of unlimited proliferation (immortality) by re-expressing the
TERT enzyme. Chromosomal instability that is generated by telomere erosion may contribute to additional mutations necessary for tumor progression.
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However, these tumors regressed rapidly upon restoration
of p53 expression. Tumor regression was due to differenti-
ation and massive senescence induction, followed by im-
mune-mediated clearance of senescent cells. These
observations may indicate that oncogene-induced senes-
cence is also involved in HCC. On the other hand, HCCs in-
duced by tet-regulated c-Myc activation in mouse liver
cells differentiate into mature hepatocytes and biliary cells
or undergo senescence [90]. Thus, senescence induction
may also be relevant to oncogene inactivation in HCC. In
this regard, c-Myc down-regulation and senescence induc-
tion in several HCC cell lines as a response to TGF-b was
observed (S. Senturk, M. Ozturk, unpublished data).
So far, all the reported examples of senescence induc-
tion in HCC cells are in the form of a telomere-independent
permanent cell cycle arrest. Until recently, it was unknown
whether replicative senescence could also be induced in
immortal cancer cells. Ozturk et al. reported recently that
immortal HCC cells can revert spontaneously to a replica-
tive senescence phenotype [91]. Immortal HCC cells gener-
ated progeny that behaved, in vitro, similar to normal
somatic cells. Such senescence-programmed progeny
lacked telomerase activity due to TERT repression (proba-
bly mediated by SIP1 gene), and displayed progressive
telomere shortening in cell culture, resulting in senescence
arrest. It will be interesting to test whether such spontane-
ous reversal of replicative immortality is involved in wellknown tumor dormancy and/or spontaneous tumor
regression.
7. Concluding remarks
Cellular senescence has gained great interest in recent
years following the demonstration that it also occurs
in vivo. It is also highly interesting that senescence can
be mediated by a large number of pathways and mole-
cules, as is the case for apoptosis. Recent ﬁndings that
implicate secreted molecules in senescence induction
strongly suggest that cellular senescence is not just a cellu-
lar event, but also a physiologically relevant process for the
whole organism. In terms of tumor biology, oncogene-in-
duced senescence that may serve as anti-tumor mecha-
nism in pre-neoplastic lesions underlines its clinical
relevance. On the other hand, induced or spontaneous
senescence that is observed in cancer cells is promising
to explore new approaches for tumor prevention and treat-
ment. The role of senescence bypass and cellular immortal-
ity in hepatocellular carcinogenesis is not well deﬁned.
But, many ﬁndings (inactivation of senescence-mediator
genes such as p53, p16INK4a and p15INK4b, as well as reacti-
vation of TERT) indicate that senescence mechanisms and
their aberrations are critically involved in HCC. We may
expect that this ﬁeld will attract more attention in coming
years for a better deﬁnition of senescence implications in
hepatocellular carcinogenesis.
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